Get the Stockscreener App
489.31
1.09%
-5.38
After Hours:
487.76
-1.55
-0.32%
Madrigal Pharmaceuticals Inc stock is traded at $489.31, with a volume of 507.98K.
It is down -1.09% in the last 24 hours and down -16.18% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$494.69
Open:
$489.75
24h Volume:
507.98K
Relative Volume:
1.43
Market Cap:
$11.11B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-19.48
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+1.84%
1M Performance:
-16.18%
6M Performance:
+68.80%
1Y Performance:
+44.64%
1-Day Range:
$480.02
$497.54
1-Week Range:
$474.86
$506.39
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
489.31 | 11.24B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Pharma News: How does INNV perform in inflationary periods2025 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Valuation Update: Will Madrigal Pharmaceuticals Inc outperform during market rallies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Breakouts Watch: What are analysts price targets for Madrigal Pharmaceuticals IncCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Bull Bear: Is Madrigal Pharmaceuticals Inc stock a value trapIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
New York State Common Retirement Fund Grows Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche - TipRanks
Madrigal Pharmaceuticals Signs Amendment to Research and Commercialization Agreement With Roche - TradingView
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Madrigal Weighs Pfizer MASH License And Insider Selling In Growth Plan - Sahm
Is Madrigal Pharmaceuticals Inc. stock a value trapTrade Entry Report & Technical Entry and Exit Alerts - mfd.ru
Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Barclays - MarketBeat
J. Safra Sarasin Holding AG Sells 4,426 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Rezdiffra Sales Milestone and Pfizer DGAT-2 Deal Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL) - Sahm
Nonalcoholic Steatohepatitis Market to Evolve Rapidly Over the Next Decade, DelveInsight Observes | Madrigal Pharmaceuticals, Novo Nordisk, 89bio - Barchart.com
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
Can Madrigal Pharmaceuticals Inc. stock double in the next yearQuarterly Trade Summary & AI Driven Stock Movement Reports - mfd.ru
MDGL: Barclays Initiates Coverage with Overweight Rating | MDGL Stock News - GuruFocus
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Recent Share Price Pullback? - Yahoo Finance
Madrigal Pharmaceuticals Lobbying And Insider Sales Put Valuation In Focus - Sahm
EFG Asset Management North America Corp. Acquires New Shares in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Taub, Madrigal Pharmaceuticals director, sells $318k in shares By Investing.com - Investing.com Canada
Carole Huntsman Sells 910 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 1,577 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Rebecca Taub Sells 647 Shares - MarketBeat
Huntsman, chief commercial officer, sells $449k in Madrigal (MDGL) By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Fundamentals Check: Will AMZE outperform during market ralliesQuarterly Trade Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Volume Recap: Will Madrigal Pharmaceuticals Inc benefit from seasonalityJuly 2025 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Trading Systems Reacting to (MDGL) Volatility - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 5.1%Here's Why - MarketBeat
Relative Strength Alert For Madrigal Pharmaceuticals - Nasdaq
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations - Sahm
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aug Decliners: Will MAYAR outperform small cap indexesJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Lobbying Update: $280,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Emerald Advisers LLC Sells 2,371 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals announces grant of inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grant Of Inducement Award Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New accounting chief at Madrigal lands stock and options deal - Stock Titan
Taub Rebecca, director at Madrigal, sells $1.09m in MDGL stock - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Sells $344,173.12 in Stock - MarketBeat
Kelley, Madrigal Pharmaceuticals general counsel, sells $344,172 in MDGL By Investing.com - Investing.com Canada
MDGL: Analyst Jonathan Wolleben Raises Price Target to $745 | MD - GuruFocus
Citizens Jmp Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $745.00 - MarketBeat
10 Analysts Have This To Say About Madrigal Pharmaceuticals - Benzinga
Citizens raises Madrigal Pharmaceuticals stock price target on strong Rezdiffra launch - Investing.com Canada
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):